References

• Kastrup A, Schlotter W, Plewnia C, Bartels M. Treatment of tics in tourette syndrome with aripiprazole. J Clin Psychopharmacol 2005; 25(1): 94–6. [CrossRef]
   PubMed Web of Science ®Google Scholar
• DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004; 26(5): 649–66. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safetyand tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61(2–3): 123–6. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Fedorowicz VJ, Fombonne E. Metabolic side effects of atypical antipsychotics in children: a literature review. J Psychopharmacol 2005; 19(5): 533–50. [CrossRef]
   Web of Science ®Google Scholar
• Harrison-Woolrych M, Garcia-Quiroga J, Ashton J. Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Saf 2007; 30(7): 569–79. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Alacqua M, Trifirò G, Arcoraci V, Germano E, Maqazu A, Calarese T, et al. Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting. Pharm World Sci 2008; 30(1): 44–50. [CrossRef]
   PubMedGoogle Scholar
• Pappagallo M, Silva R. The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol 2004; 14(3): 359–71. [CrossRef]
   Web of Science ®Google Scholar
• Rugino TA, Janvier YM. Aripiprazole in children and adolescents: clinical experience. J Child Neurol 2005; 20(7): 603–10.
   Web of Science ®Google Scholar
• Correl CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007; 46(6): 687–700. [CrossRef]
   Web of Science ®Google Scholar
• Kirino E. Efficacy and safety of aripiprazole in child and adolescent patients. Eur Child Adolesc Psychiatry. 2012; 21(7): 361–8. [CrossRef]
   Web of Science ®Google Scholar
• Dogangun B, Kayacetin G, Kayaalp L. A reviewabout the use ofaripiprazole in children and adolescents. Turkish Journal of Child and Adolescent Mental Health 2008; 15(3): 163–75. (Turkish)
   Google Scholar
• Findling RL, Robb A, Nyilas M, Forbes NA, Jin N, Ivanova S, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 165(11): 1432–41. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Durkin JP. Aripiprazole in the treatment of bipolar disorder in children and adolescents. J Child Adolesc Psychopharmacol 2004; 14(4): 505–6. [CrossRef]
   Web of Science ®Google Scholar
• Findling RL, Youngstrom EA, McNamara NK, Stansbrey RJ, Wynbrandt JL, Adegbite C, et al. Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder. J Clin Psychiatry 2012; 73(1): 57–63. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Biederman J, McDonnell MA, Wozniak J, Spencer T, Aleardi M, Falzone R, et al. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr 2005; 10(2): 141–8.
   Web of Science ®Google Scholar
• Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder. J Am Acad Child Adolesc Psychiatry 2009; 48(11): 1110–9. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Basgul S, Uneri Ozden. Poster Communication. 14th International Congress of ESCAP—European Society for Child and Adolescent Psychiatry 11–15 June 2011, Finland.
   Google Scholar
• Murphy TK, Bengtson MA, Soto O, Edge PJ, Sajid MW, Shapira N, et al. Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol 2005; 8(3): 489–90. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Duane DD. Aripiprazole in childhood and adolescence for Tourette syndrome. J Child Neurol 2006; 21(4): 358. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry 2008; 69(Suppl 4): S9–S14.
   PubMed Web of Science ®Google Scholar
• Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006; 11(7): 622–32. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Findling RL, Short EJ, Leskovec T, Townsend LD, Demeter CA, McNamara NK, et al. Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008; 18(4): 347–54. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Ercan ES, Uysal T, Ercan E, Ardic UA. Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study. Pharmacopsychiatry 2012; 45(1): 13–9. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Bildik T, Ozbaran NB, Kucukkose M, Ardic UA. Aripiprazole use in children and adolescents: a case series. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2010; 20(1): 84–93. (Turkish)
   Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental health disorders (4th). Washington DC: Am Psychiatric Publishing, 1994.
   Google Scholar
• Guy W. Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health and Human Services Publication (ADM) 1976; 218–22.
   Google Scholar
• Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989; 28(4): 566–73. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004; 14(3): 455–63. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Spencer T, Doyle R, Joshi G, Hammerness P, Kotarski M, et al. An openlabel trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr 2007; 12(9): 683–89.
   Web of Science ®Google Scholar
• Tramontina S, Zeni CP, Pheula GF, de Souza CK, Rohde LA. Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial. CNS Spectr 2007; 12(10): 758–62.
   Web of Science ®Google Scholar
• Barzman DH, Del Bello MP, Kowatch RA, Gernert B, Flek DE, Pathak S, et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child Adolesc Psychopharmacol 2004; 14(4): 593–600. [CrossRef]
   Web of Science ®Google Scholar
• Adelaide SR, Candace A, Elizabeth EB, George M, Carlos RF, Suja M, et al. Safety and Tolerability of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder in Pediatric Subjects (6–17 Years Old): Results From a Pooled Analysis of 2 Studies. Prim Care Companion CNS Disord 2011; 13(1): 1–9.
   Google Scholar
• Lyon GJ, Samar S, Jummani R, Hirsch S, Spirgel A, Goldman R, et al. Tourette bozukluğu olan çocuk ve ergenlerde aripiprazol: Bir açık etiketli güvenlik ve tolerabilite çalışma. J Child Adolecs Psvchopharmacol Ara 2009; 19(6): 623–33. [CrossRef]
   PubMed Web of Science ®Google Scholar